IQVIA Laboratories

Run clinical trials with greater control, confidence, and consistency. IQVIA Laboratories' fully digital e Requisition solution streamlines workflows, improves data quality, and reduces site queries by up to 96% for stronger oversight across studies. Find out how e Requisition is changing the game for end-to-end clinical laboratory workflows: https://lnkd.in/d8h4gu-E

PET imaging reveals wholebody biodistribution of radiopharmaceuticals in real time, enabling early assessment of tissue targeting, clearance, and organ accumulation. In preclinical oncology models, PET (and SPECT) allows noninvasive, quantitative tracking of radiolabeled compounds supporting critical decisions on efficacy and safety during preclinical discovery and development. By combining imaging with dosimetry approaches, researchers can better understand drug exposure, optimize delivery, and predict clinical translation with greater confidence. https://hubs.ly/Q04lz-4l0

Speed wins in discovery, and we’re redefining what fast looks like. By embedding generative AI and advanced automation across the DMTA cycle, we’ve: · Cut assay development timelines by up to 50% · Expanded chemical space exploration · Increased success rates per cycle The result? A scalable, AI-enabled 5-day DMTA cycle driving real-world projects. Explore our approach to accelerating the DMTA cycle: https://lnkd.in/enV5QzCg

An estimated 400,000 children worldwide develop cancer each year. This is why all oncology therapies require efficacy and safety testing in pediatric cancers before approval. Our pediatric PDX portfolio provides over 400 well-characterized and RACE Act-compliant models to ensure your therapy demonstrates meaningful therapeutic impact in a translational disease context. https://hubs.ly/Q04m1ltP0

Streamline clinical trial operations. Maximize the value of biospecimens. Unlock critical insights. By integrating AI to deliver instant, actionable insights, our innovative Labmatrix® platform empowers you to: • Ask questions and get answers without the need for building queries • Zoom in on the datasets and metrics that matter • Instantly generate integrated mini dashboards to visualize related data Find out more in our fact sheet: https://lnkd.in/dv78FCwJ

Clinical programs are expanding genomic endpoints but cost still limits scale. Not anymore! Check out what's possible here: https://lnkd.in/e7DX7_Fk

Discover how IQVIA Laboratories' Site Lab Navigator is revolutionizing investigator site support. By automating lab workflows and reducing administrative burdens, we're accelerating the path to high-quality results. Unlock the future of clinical trials and learn more about Site Lab Navigator here: https://lnkd.in/d8h4gu-E

As biomarker-based clinical research becomes commonplace, biobanks are expected to drive investigational research. But is your biobank ready? Our Next Gen Biobanking software platform provides robust on-site management of sample storage, workflows, and data management, along with the ability to connect to external lab and biobank partners, for a completely unified sample-management system. Visit our webpage to learn more: https://lnkd.in/dJ8CET9e

PET imaging enables realtime visualization of tumor biology, helping you assess drug distribution, target engagement, and efficacy earlier in oncology drug discovery. Combining PET with CT and additional bioanalysis endpoints, PET supports a deeper understanding of mechanism of action and therapeutic impact, strengthening translation to the clinic and improving decisionmaking confidence. https://hubs.ly/Q04lz-4l0

In January 2026, the FDA issued draft guidance outlining how MRD negativity in complete response may support accelerated approval in multiple myeloma. This moderated, on-demand panel discussion examines: • What the FDA guidance enables • What regulators can expect • How MRD can be operationalized as a primary endpoint Watch now: https://lnkd.in/eGNHpGkv